Less Than A Quarter Of Patients In National Rheumatology Registry Were Screened For HBV Or HCV Prior To Initiating Biologics Or New Synthetic DMARDs, Researchers Say

Healio (11/13, Laday) reports, “Less than a quarter of patients in” the American College of Rheumatology’s Rheumatology Informatics System for Effectiveness “were screened for hepatitis B or C prior to initiating biologics or a new synthetic DMARDs, despi...